Your Health. Your Family. Your Choice.
Administered by: Other Purchased by: ?
Life Threatening? No
Write-up: nausea; Vomiting; Headache; Blurred vision; This is a spontaneous report from a contactable consumer received from the Regulatory Agency. The regulatory authority report number is GB-MHRA-WEBCOVID-202106041931044710-8IILT, Safety Report Unique Identifier GB-MHRA-ADR 25423438. A 28-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 03Jun2021 as dose1, single for COVID-19 immunisation, at the age of 28-years-old. Medical history included multiple allergies. Patient had not had symptoms associated with COVID-19 and was not enrolled in clinical trial. Patient was not pregnant and was not currently breastfeeding. Concomitant medications included fexofenadine taken for multiple allergies from 09Aug2020 to an unspecified stop date; ethinylestradiol, levonorgestrel (RIGEVIDON) taken for an unspecified indication from 11Oct2019 to an unspecified stop date. The patient experienced nausea on 04Jun2021, vomiting, headache and blurred vision on 03Jun2021. The events were reported as serious as important medical events. It was reported that patient started with headache within half an hour, 5 hours later severe headache, blurred vision, vomiting. By morning after slight nausea and headache. The patient underwent lab tests and procedures which included COVID-19 virus test: negative on 04Jun2021. The patient was recovering from nausea and headache, had recovered from vomiting on 03Jun2021 and from blurred vision on 04Jun2021. No follow-up attempts are possible. Information about batch/lot number cannot be obtained.
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166